BioMed Central © 2010 Pourgholami et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

RESEARCH ARTICLE

Potent inhibition of tumoral hypoxia-inducible factor 1α by albendazole

Mohammad H Pourgholami1, Zhao Y Cai1, Samina Badar1, Kiran Wangoo1, Marianne S Poruchynsky2 and David L Morris*1

Abstract

Background: Emerging reports suggest resistance, increased tumor invasiveness and metastasis arising from treatment with drugs targeting vascular endothelial growth factor (VEGF). It is believed that increased tumoral hypoxia plays a prominent role in the development of these phenomena. Inhibition of tumoral hypoxia inducible factor (HIF-1α) is thus becoming an increasingly attractive therapeutic target in the treatment of cancer. We hypothesized that the anti-VEGF effect of albendazole (ABZ) could be mediated through inhibition of tumoral HIF-1α.

Method: In vitro, the effects of ABZ on HIF-1α levels in human ovarian cancer cells (OVCAR-3) were investigated using hypoxic chamber or desferrioxamine (DFO) induced-hypoxia. In vivo, the effects of ABZ (150 mg/kg, i.p., single dose) on the tumor levels of HIF-1α and VEGF protein and mRNA were investigated by western blotting, RT-PCR and real time-PCR.

Results: In vitro, ABZ inhibited cellular HIF-1α protein accumulation resulting from placement of cells under hypoxic chamber or exposure to DFO. In vivo, tumors excised from vehicle treated mice showed high levels of both HIF-1α and VEGF. Whereas, tumoral HIF-1α and VEGF protein levels were highly suppressed in ABZ treated mice. Tumoral VEGFmRNA (but not HIF-1αmRNA) was also found to be highly suppressed by ABZ.

Conclusion: These results demonstrate for the first time the effects of an acute dose of ABZ in profoundly suppressing both HIF-1α and VEGF within the tumor. This dual inhibition may provide additional value in inhibiting angiogenesis and be at least partially effective in inhibiting tumoral HIF-1α surge, tumor invasiveness and metastasis.

Background

Amongst the vast array of proangiogenic molecules identified, VEGF has been shown to play a pivotal role in tumor angiogenesis. VEGF is a potent stimulator of endothelial cell survival, mitogenesis, migration and differentiation [1,2]. Angiogenesis inhibitors targeting VEGF have shown anticancer activity in preclinical and clinical trials. Several VEGF inhibitors have been approved by the US Food and Drug administration for the treatment of tumors or age-related macular degeneration [3,4]. However, recently emerging reports suggest that the effects of these drugs in cancer are only transitory, not producing enduring efficacy in terms of either tumor shrinkage or dormancy or long term survival, thus resulting in eventual drug resistance, vascular recovery and relapse to progressive tumor growth [5-7]. A number of contributing mechanisms have been proposed including up-regulation of fibroblast growth factor (FGF), matrix metalloproteinases (MMPs) and the induction of HIF-1α [6,8]. The most important mediator identified to date of the cell's response to reduced oxygen availability, HIF-1α is preserved and activated in response to reduced oxygen availability [9]. By affecting the expression of a wide array of genes, HIF-1α plays a central role in angiogenesis and in regulating the adaptation and survival of tumors [10,11]. Perhaps to some extent this is because transcriptional regulation of VEGF is critically dependent on HIF-1α. Results from several studies have provided compelling evidence that hypoxia-triggered up-regulation of other proangiogenic factors in the presence of anti-VEGF agents can restimulate tumor angiogenesis through VEGF-dependent or VEGF independent pathways [6,12,13]. More importantly, HIF-1α induction by

* Correspondence: david.morris@unsw.edu.au
1 Cancer Research laboratories, University of New South Wales Department of Surgery, St George Hospital, Sydney, NSW 2217, Australia
Full list of author information is available at the end of the article
hypoxia has been associated with the emergence of a more aggressive tumor phenotype [14]. On this basis, drugs that inhibit VEGF and angiogenesis through the inhibition of HIF-1α may provide therapeutic benefit over those which target the VEGF or its signaling pathway only.

Albendazole, methyl 5-propylthio-1H-benzimidazole-2-yl carbamate, is a benzimidazole carbamate originally developed as a veterinary product back in 1975 and despite its extensive use in man and farm animals, few adverse events have been associated with its use [15,16]. Its anthelmintic action has been attributed to binding to the helminth β-tubulin, leading to depolymerization, cell cycle arrest and death [17,18]. Because of their interaction with the microtubules, in recent years, benzimidazole carbamates such as albendazole and mebendazole have been under investigation as anticancer agents. Cell culture and animal studies utilizing human cancer cells have revealed that both these agents are potent inducers of apoptosis and inhibitors of tumor growth [19-23]. More recently, using an experimental model of ovarian cancer with malignant ascites formation, we demonstrated that, chronic treatment with ABZ leads to suppression of VEGF levels, inhibition of malignant ascites formation and arrest of tumor growth [24,25]. In the current study we sought to investigate if the observed ABZ anti-VEGF effect is mediated through the inhibition of the HIF pathway. Herein, we report that, in vitro experiments performed using hypoxic chamber and DFO, provided evidence for the anti-HIF-1α activity of ABZ. Then, study of the effects of a single dose of ABZ on tumoral HIF-1α and VEGF expression revealed profound suppression of both HIF-1α and VEGF protein levels. Thus, results from this study demonstrate that ABZ is a potent inhibitor of HIF-1α under both in vitro and in vivo conditions.

Methods

Chemicals and antibodies

Unless otherwise stated, all drugs and chemicals used in this study were obtained from Sigma-Aldrich (Australian subsidiary, Sydney). The following primary antibodies were used through out this study: HIF-1α (H-206) rabbit polyclonal IgG (Santa Cruz Biotechnology), VEGF (C-1) mouse monoclonal IgG (Santa Cruz Biotechnology, Sydney, Australia.), Monoclonal anti-β-actin (Sigma-Aldrich). Secondary antibodies were goat anti rabbit IgG HRP (Santa Cruz Biotechnology) and anti mouse IgG peroxidase (Sigma-Aldrich).

Cell culture

The human ovarian cancer cells (OVCAR-3), originally obtained from the American Type Culture Collection (ATCC) were prepared for in vitro and in vivo growth experiments as previously described [24]. Cells were maintained in RPMI 1640 medium with 2 mM l-glutamine, 2 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, 1 mM sodium pyruvate, 0.01 mg/mL bovine insulin, supplemented with 100 units/mL penicillin and 100 units/mL streptomycin and 10% FBS in a humidified atmosphere at 37°C.

In vitro hypoxia tests

OVCAR-3 cells (3 × 10⁶) seeded in 75 cm² flasks were grown for 72 h at 37°C to 80% confluency. Cells were treated with ABZ (0 -1 μM) before being placed in a sealed modular hypoxic chamber (Billups-Rothenburg, Del Mar, CA) flushed with 1% O2, 5% CO2 and 94% N2. The chamber was then placed in an incubator at 37°C for 4 h. For induction of chemical hypoxia, the same procedure was used, except that instead of placement in hypoxic chamber, cells were treated with the chemical hypoxic agent desferrioxamine (DFO, 100 μM) for 4 h. DFO is a well established hypoxymimetic agent [26]. Cells not exposed to hypoxia or DFO were run in parallel as controls. Following treatment, cells were washed with PBS and scraped into RIPA buffer (300 μL). Lysates were centrifuged (8000 rpm, 4°C, 10 min) and stored at -80°C for analysis. HIF-1α and VEGF protein expressions were determined by western blot analysis, while RT-PCR and real time PCR were used to determine mRNA levels.

Establishment of i.p. xenograft

Intraperitoneal tumors were grown in 6 week old female nude athymic Balb C nu/nu mice (Animal Resources Centre, Perth, Western Australia). Each mouse was injected i.p. with 10 million OVCAR-3 cells suspended in 1 mL of the medium. Animals were housed under complete aseptic conditions, fed autoclaved pellets and sterile water ad libitum. Health status of each animal was monitored daily and all animal procedures were conducted in conformity with institutional animal ethics committee guidelines (University of New South Wales, Sydney, Australia).

Drug treatment

Three weeks post cell inoculation, animals were randomly assigned to one of the 6 treatment groups (6 mice/group). Before proceeding with drug treatment, animals were subjected to peritoneal lavage (2 mL of sterile normal saline injected i.p. and aspirated immediately after kneading). Mice were then immediately treated i.p. (1 mL/20 g body weight) with either the vehicle [0.5% w/v hydroperoxymethyl cellulose (HPMC)] or ABZ (150 mg/kg suspended in HPMC) followed by euthanasia at the predetermined time. Group 1 animals were euthanized immediately after vehicle treatment. Groups 2-6 were treated with ABZ and euthanized at 1, 6, 24, 48 or 72 h
post injection respectively. Following euthanasia, peritoneal cavity was washed, tumors were excised, rapidly snap frozen in liquid nitrogen and stored at -80°C for subsequent analysis. Tumors were analysed for the expression of VEGF and HIF-1 protein and mRNA.

### Western blot analysis
Equivalent amounts of whole cell extracts (or tumor protein) were resolved in SDS-PAGE (10% for HIF-1α and 12% for VEGF) and transferred to a PVDF membrane. The membrane was blocked in 5% non-fat dry milk in TBST and incubated (2 h) with indicated primary antibodies (HIF-1α and VEGF, 1:200), followed by incubation (1 h) with secondary anti body, goat anti-rabbit (1:5000) or anti-mouse secondary antibody (1:160,000) (Sigma-Aldrich) for HIF-1α and VEGF respectively. Immunoreactivity was visualised by enhanced chemiluminescence reagent (Perkin Elmer Cetus, Foster City, CA, USA). To demonstrate equal loading, blots were stripped and reprobed with a specific antibody recognizing β-actin (1:5000 dilution; Sigma-Aldrich).

### Determination of mRNA by RT-PCR
Mice tumor extracts were examined for the expression of VEGF and HIF-1α mRNA by reverse transcription-PCR. Total RNA was isolated from the cells using the highly pure RNA isolation kit according to the protocol provided by the manufacturer (Invitrogen, Sydney, Australia). Primers for the amplification of VEGF and HIF-1α were constructed based on the following sequence: VEGF sense: 5'-CAC ATA GGA GAG ATG AGC TTC-3'; VEGF anti-sense: 5'-CCC TGC AGT AGG TTT GAG GAC TTG CGC TTT CA-3'. Amplification of VEGF and HIF-1α mRNA by reverse transcription-PCR. Determination of mRNA by Real-Time PCR was performed using TRizol reagent. cDNA synthesis was performed on RNA (1 µg) using Super Script III First - Strand Synthesis Super Mix kit (Invitrogen Life Technologies). Real time was performed in a Roter Gene 3000 (Corbett Life Science, Mortlak, Australia) using SYBR Green ER qPCR Super Mix Universal kit (Invitrogen life technologies) as per supplier protocol. Primers used to amplify specific gene products were GAPDH Sense 5’GGG CTG AGT AGC AGC TCG TGG AG 3’ GAPDH Anti-sense 5’CAG GTG GTG GTG GTG CAG GAG GAG G-3’; HIF-1α Sense 5’-CCA GTG AGC TTC CTT CCT GGA GTA TCA GT-3'; Anti sense 5’-TTT GAG GAC TTG CGC TTT CA-3’. Amplification reaction used for HIF-1 were performed as previously described [27]. Data obtained are expressed as CT which is the PCR cycle number at which the accumulated fluorescent signal in each reaction crosses a threshold above background. The relative expression levels were calculated relative to the control using the comparative Ct (ΔΔCt) method where the relative expression is calculated as 2-ΔΔCt.

### Statistical analysis
GraphPad Prism version 5.0 was used for data analysis. All data are reported as the mean ± s.e.m. In vitro data were analysed using Student’s t test followed by Tukeys. Animal data were analysed using Mann-Whitney U test. Effects were considered to be statistically significant at p < 0.05.

### Results

**ABZ does not affect HIF-1α under normoxic conditions**

We first examined the effect of ABZ on HIF-1α under normoxic cell culture conditions. Here, OVCAR-3 cells grown in culture were treated with ABZ (0.1-1 µM) for 4 h and then examined for the expression of HIF-1α protein. The cells did not express measurable quantity of HIF-1α protein under normoxic conditions and their treatment with ABZ had no affect on HIF-1α protein expression (Figure 1A).

**ABZ treatment inhibits hypoxia-induced accumulation of HIF-1α protein in vitro**

We next examined the effect of ABZ on hypoxia-induced HIF-1α accumulation in vitro. ABZ treated cells placed in hypoxic chamber for 4 h were analysed for the expression of HIF-1α. Hypoxic conditions led to dramatic increase in HIF-1α levels while, pre-treatment of cells with ABZ inhibited HIF-1α accumulation in a dose-dependent manner (Figure 1B). Under these conditions, and compared to vehicle treated cells, the HIF-1α levels were reduced by 41% (p < 0.05) and 79% (p < 0.001) in 0.1 and 1 µM ABZ treated cells respectively.

Utilizing DFO, chemically induced hypoxia was used to obtain further evidence on the in vitro effect of ABZ on
cellular HIF-1α expression. Exposure of cells to the hypoxia mimetic agent DFO, led to 3 fold increase in HIF-1α protein expression. Pre-treatment of cells with ABZ led to concentration-dependent reduction in HIF-1α levels (Figure 1C). Compared to vehicle treated controls, HIF-1α protein content in cells exposed to the 1 μM ABZ were profoundly reduced (p < 0.001).

**ABZ treatment diminishes tumoral HIF-1α expression**

In order to determine if these *in vitro* observations do translate into *in vivo* anti-HIF effects, tumor bearing mice were given a single dose of ABZ and their tumors were excised at various time-points post drug administration. Using western blot analysis, HIF-1α levels in these tumors were then assessed. As shown in Figure 2A, tumoral HIF-1α protein levels were highly reduced for up to 48 h post ABZ administration. Peak ABZ anti-HIF-1α effect was found to be in tumors harvested at 24 h post drug administration. To find out if the HIF-1α suppression was a biological consequence of HIF-1mRNA inhibition by ABZ, using RT-PCR, the tumor samples were examined for HIF-1mRNA expression. Except for the 24 h treated tumors, no reduction in HIF-1mRNA could be detected (Figure 2B). To verify this, the 24 h tumor samples were further analysed by real-time PCR. Results obtained show no difference in tumoral HIF-1mRNA expression between the vehicle and ABZ treated groups (Figure 2C).

**ABZ inhibits tumoral accumulation of VEGF protein and mRNA**

VEGF expression is tightly controlled by HIF-1α, thus a reduction in HIF-1α expression should be directly reflected in VEGF expression. We therefore examined the tumor tissues for the expression of VEGF. As depicted in Figure 3A, VEGF is highly expressed in these tumors and treatment with a single dose of ABZ led to dramatic and time-dependent decline on tumoral VEGF levels. This effect paralleled the time-dependent suppression of HIF-1α with the ABZ effect peaking during the 24-48 h post
drug administration period (in 24 and 48 h samples p < 0.001 compared to zero time controls). To confirm that the ABZ effect on the VEGF levels resulted from inhibition of transcriptional activity, tumoral VEGFmRNA levels were examined by RT-PCR. As illustrated in Figure 3B, VEGFmRNA levels were highly suppressed in the 24 and 48 h tumor samples. These results provide strong evidence in support of anti-HIF activity of ABZ in vivo and hence reveal the mechanism behind its potent anti-VEGF effects.

Discussion
Chronic ABZ treatment has recently been shown to produce antitumor and anti-VEGF effects. The results from the present study reveal that ABZ inhibits HIF-1α accumulation and VEGF production after acute administration. We examined the effects of ABZ on HIF-1α levels in cell culture under both normoxic and hypoxic conditions. Although the HIF-1α gene is constitutively transcribed, under normoxic conditions HIF-1α protein is virtually undetectable due to its oxygen-dependent degradation by the propyl hydroxylases [28]. However, exposure to hypoxia stops HIF-1α degradation and hence leads to its rapid accumulation in the cell [29]. Similarly, treatment of cells with DFO (an inhibitor of propyl hydroxylases) also causes cellular accumulation of the HIF-1α protein [26]. Herein, we found that pre-treatment of OVCAR-3 tumor cells with ABZ inhibits hypoxia or DFO-induced HIF-1α accumulation. More importantly, the present study revealed that, in vivo administration of ABZ as a single dose leads to profound suppression of tumoral HIF-1α and VEGF.

It has been well established that solid tumor growth is angiogenesis dependent and hypoxia is the major pathophysiologic condition that regulates angiogenesis [10]. Tumor hypoxia arises as a result of increased meta-
bolic activity and oxygen consumption by the rapidly proliferating tumor cells. HIF-1α is a transcriptional activator that mediates adaptive responses to hypoxia through the induction of a number of growth factors and cytokines [2,9]. In solid tumors, HIF-1α is a potent inducer of VEGF which then plays a pivotal role in the process of angiogenesis [30-32]. Based on this, targeting tumoral HIF-1α is under intense investigation as a therapeutic strategy to inhibit angiogenesis and tumor growth.

In rapidly growing solid tumors reduced oxygen availability leads to inhibition of propyl hydroxylases, a dramatic surge in HIF-1α protein levels and consequently induction of VEGF mRNA and protein [33]. Up-regulation of VEGF leads to a series of events culminating in the formation of new vessels to support the rapidly dividing cells with the necessary oxygen and nutrients [9,34]. In addition to up-regulation of VEGF expression, HIF-1α itself has been found to be an important mediator of survival and angiogenesis and its over expression in the majority of the human cancers has been associated with patient mortality and poor response to treatment [35,36]. Based on this, targeting tumoral HIF-1α is under intense investigation as a therapeutic target for cancer chemotherapy.

Furthermore, emerging experimental and clinical data from VEGF-targeted therapies are suggesting development of resistance and increased tumor invasiveness and metastasis [6,12,37]. While it is entirely possible that the resistance mechanisms are diverse and depend on tumor type and the drug employed, up-regulation of several well-defined signaling pathways such as placental growth factor (PIGF), fibroblast growth factor (FGF), matrix metalloproteinases (MMPs), notch and the HIF pathway have been suggested [6,8]. In line with this, recent studies have implicated the hypoxia/HIF-1α as an instigator of invasion and metastasis [14,38,39]. Thus tumoral HIF-1α inhibition is becoming an increasingly attractive therapeutic target in the treatment of cancer [40].

In this study we demonstrate for the first time that ABZ is a potent inhibitor of HIF-1α under both \textit{in vitro} and \textit{in vivo} conditions. Under cell culture conditions, ABZ inhibited hypoxia and DFO-induced accumulation of HIF-1α. \textit{In vivo}, ABZ treatment led to diminished tumoral HIF-1α levels. In line with this, tumoral VEGF levels were also profoundly suppressed. Further trials are needed to show if inhibition of the HIF-VEGF axis by ABZ provides additional therapeutic benefit over agents that only inhibit VEGF or it's down stream signalling pathways.

**Conclusion**

ABZ, a benzimidazole carbamate with extensive clinical use as an anthelmintic, was shown in this study to be a potent inhibitor of tumoral HIF-1α. Both VEGF and HIF-1α are thought to be crucial mediators of angiogenesis and tumor growth. Anti-VEGF agents may induce tumor resistance. Inhibition of tumoral HIF-1α by ABZ may thus prove to be advantageous in HIF induced anti-VEGF resistance.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

The author MHP designed the investigation, analysed the data and prepared the manuscript. The authors ZYC, SB and KW performed the experiments and...
also took part in data analysis and discussions. Authors, MSP and DLM provided important input into designing experiments, review and editing of the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgements
This work was supported in part by a grant-in-aid from the "Lady Fairfax Foundation" Sydney, NSW, Australia.

Author Details
1 Cancer Research laboratories, University of New South Wales Department of Surgery, St George Hospital, Sydney, NSW 2127, Australia and 2 Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA

Received: 6 January 2010 Accepted: 15 April 2010
Published: 15 April 2010

References
1. Ferrara N: VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl 3):11-6.
2. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl 3):4-10.
3. Crawford Y, Ferrara N: VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009, 335(1):261-9.
4. Crawford Y, Ferrara N: Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009, 30(12):624-30.
5. Kerbel RS: Tumor angiogenesis. N Engl J Med 2008, 358(19):2039-49.
6. Dempke WC, Henemann V: Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 2009, 45(7):117-28.
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15(3):232-9.
8. Ellis LM, Hicklin DJ: Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008, 14(20):6371-5.
9. Semenza GL: Hypoxia-inducible factor 1 and cancer pathogenesis. JLBMB Life 2008, 60(9):591-7.
10. Liao D, Johnson RS: Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007, 26(2):281-90.
11. Maukami Y, Kohgo Y, Chung DC: Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007, 13(10):5670-4.
12. Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8(4):299-309.
13. Francia G, Emenegger U, Kerbel RS: Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. Cancer Cell 2005, 11(1):3-5.
14. Du R, Lu KV, Petriech C, Liu P, Gans R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G: HIF-1 alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13(3):206-20.
15. Morris DL, Jourdan JL, Pourgholami MH: Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/ high incidence of neutropenia. Oncology 2001, 61(1):42-6.
16. Horton J: Albendazole: a broad spectrum anthelmintic for treatment of individuals and populations. Curr Opin Infect Dis 2002, 15(6):599-608.
17. Lacey E, Brady RL, Prichard RK, Watson TR: Comparison of inhibition of polymerisation of mammalian tubulin and heminthic ovicidal activity by benzimidazole carbamates. Vet Parasitol 1987, 23(1-2):105-19.
18. Lacey E: The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. Int J Parasitol 1988, 18(7):885-936.
19. Pourgholami MH, Woon L, Almajad R, Akhter J, Bowery P, Morris DL: In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001, 165(1):143-9.
20. Pourgholami MH, Akhter J, Wang L, Lu Y, Morris DL: Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 2005, 55(5):425-32.
21. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA: Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 2002, 8(9):2963-9.
22. Martarelli D, Pompei P, Baldi C, Mazzoni G: Mebendazole inhibits growth of human adenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol 2008, 61(5):809-17.
23. Sasaki J, Ramesh R, Chada S, Gomoy Y, Roth JA, Mukhopadhyay T: The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 2002, 1(3):1201-9.
24. Pourgholami MH, Yan Cai Z, Lu Y, Wang L, Morris DL: Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 2006, 12(6):1928-35.
25. Pourgholami MH, Cai ZY, Wang L, Badar S, Links M, Morris DL: Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole. Cancer Invest 2009, 27(2):171-7.
26. Hilsila M, Koivunen P, Xu L, Seeley T, Kivirikko KI, Myllyharju J: Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. Faseb J 2005, 19(10):1308-10.
27. Khalizadeh A, Wangso KT, Morris DL, Pourgholami MH: Epitholine-paclitaxel resistant leukemic cells CEM/EpoB380 are sensitive to albendazole: Involvement of apoptotic pathways. Biochem Pharmacol 2007, 74(3):407-14.
28. Jaakola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kneisheim A, Hebstreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292(5516):468-72.
29. Callipina M, Zhou J, Schnitzer S, Metzen E, Lohr C, Deitmer JW, Brune B: Nitric oxide reverses desferrioxamine- and hypoxia-evoked HIF-1 alpha accumulation--implications for prolyl hydroxylase activity and iron. Exp Cell Res 2005, 306(1):274-84.
30. Sheweiki D, Irin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-activated angiogenesis. Nature 1992, 359(6398):843-5.
31. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):182-6.
32. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6(4):273-86.
33. Semenza GL: HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000, 19(1-2):59-65.
34. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3(10):721-32.
35. Mellito G: Inhibiting hypoxia-inducible factor 1 as a cancer target. Mol Cancer Res 2006, 4(9):1001-5.
36. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16(9):4604-13.
37. Paez-Ribes M, Allen E, Hudson J, Takeda A, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(3):220-31.
38. Carins RA, Hill RP: Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res 2004, 64(20):6054-61.
39. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM: Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3(4):347-61.
40. Semenza GL: Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007, 12(19-20):853-9.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10/143

Cite this article as: Pourgholami et al., Potent inhibition of tumoral hypoxia-inducible factor 17 by albendazole BMC Cancer 2010, 10:143

doi: 10.1186/1471-2407-10-143